Ding et al. found that the same nuclear receptor facilitated prostate cancer cell migration and invasion, accompanied by the upregulation of CCL2/CCR2 signals (Ding et al. (2015a), and possessed potential as a therapeutic target (Ding et al., 2015b). This evidence concerns the gene CCL2 and Familial prostate cancer.